Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Research and science related to a minor improvement in hair growth caused by the use of verteporfin, as well as potential treatments such as Minoxidil, Finasteride, and RU58841.

Pelage Pharmaceuticals announced positive Phase 2a trial results for PP405 in hair loss therapy. The conversation discusses the delay in publishing full results and the need for further trials and approvals.

PP405 is a new hair loss treatment that may outperform minoxidil and finasteride by growing thick hair in bald areas within four weeks. Its release is expected around 2028, but concerns about its long-term efficacy and cost remain.

FLEAVA is accused of scamming customers by enrolling them in unwanted monthly subscriptions for Advanced Copper Peptide without consent. Many users struggled to get refunds and reported ongoing charges despite cancellation requests.

The conversation discusses the use of Verteporfin in treating hair loss. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

The conversation discusses potential hair loss treatments, including Setipiprant, Bimatoprost, and Follicept. The user encourages signing up for Follicept, which may come to market soon.

A human trial involving verteporfin for hair regeneration, with the results showing some regrowth of 1-2 hairs in an area where a follicular unit was extracted. The conversation also suggested that future studies should involve higher doses and more frequent injections.

User discusses verteporfin for hair regrowth through "super microneedling" and preventing scarring. They mention a case of an old man regrowing hair after a head injury and suggest verteporfin could recreate this result.

KX-826/pyrilutamide is undergoing an additional one-year safety and efficacy trial in China after a six-month study. Some participants speculate on the reasons for the extended trial and discuss the potential of other treatments.

The conversation discusses Kintor's initiation of a new Phase 3 trial to assess the long-term safety of Pyrilutamide (KX-826) for hair loss, which will last 52 weeks. Specific treatments mentioned include Pyrilutamide.

Pelage is developing a topical hair follicle stem cell therapy, PP405, for non-scarring alopecias like androgenetic alopecia, with Phase III trials planned and a potential market launch by 2027. The treatment may not require continuous use after initial regrowth.

PP405 shows promise in hair loss treatment, but stem cell therapy using adipose-derived stem cells and ATP also successfully reversed androgenetic alopecia in mice. Stem cell therapy is costly, and some doubt the effectiveness of PP405 based on press releases.

The conversation is about whether doctors are offering hair transplants using verteporfin. Dr. Bargouthi in Jordan and Dr. Bloxham in New York are currently conducting trials on it.

A new topical treatment, PP405, shows promising results for hair regrowth, potentially outperforming existing treatments like finasteride and minoxidil. However, it may still need to be combined with DHT blockers for optimal results, and its long-term effectiveness remains uncertain.

Verteporfin is discussed as a potential treatment for scarring alopecia. Minoxidil is suggested as an alternative treatment.

Pelage is moving to Phase III clinical trials for PP405, a hair loss treatment, with results to be presented at a medical meeting. Users express skepticism and hope, comparing it to existing treatments like Minoxidil and finasteride, while discussing the potential for new hair growth in previously bald areas.

A user had a bad experience with MV Supplements when their Pyril powder and ethanol order leaked during shipping, making the products unusable. Despite contacting support and providing evidence, the company's return policy did not allow for a refund or replacement.

PP405 is moving to late-stage trials, showing potential for hair regrowth, with 31% of male patients experiencing a 20% increase in hair density. Veradermics is developing an oral minoxidil version, and there is interest in combining treatments for better results.

PP405 is considered a promising potential cure for hair loss, with phase 2 trial results expected in February 2025. Hair cloning is also discussed as a potential ultimate solution, despite significant scientific challenges.

Verteporfin is discussed as a potential treatment for hair regrowth, but skepticism exists about its effectiveness in regenerating extracted hair follicles. The conversation also mentions the possibility of needing a hair transplant by 2028.

Hopeful treatments for hair loss, including Verteporfin, Androgen Receptor Degradation, and SCUBE3. These treatments offer potential solutions to slow or stop the effects of androgens on the scalp.

Dr. Bloxham reported that Verteporfin is regenerating hair follicles. It might be a potential cure for hair loss.

OP experienced thicker hair and less shedding with Nutrafol Women’s Balance but had flushing due to ingredients, and is considering switching to Viviscal Pro with saw palmetto. A user shared that Viviscal increased shedding for both him and his girlfriend, and suggested stopping Nutrafol if the hair loss is due to Telogen effluvium.

Pelage plans to release phase 2 results and start phase 3 trials for PP405 in 2050, but skepticism remains due to past delays and unfulfilled promises. Users express frustration over the lack of progress in hair loss treatments, mentioning Minoxidil, finasteride, RU58841, CB-03-01, and Fluridil.